<DOC>
	<DOC>NCT00711321</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term tolerability and -safety of AFFITOPE AD02 applied during AFFiRiS 002</brief_summary>
	<brief_title>Long-term Safety and Tolerability of AFFITOPE AD02</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Written informed consent signed and dated by patient and caregiver Patients having participated in AFF002 and having received at least 1 vaccination with AFFITOPE AD02 Availability of a partner/caregiver knowing the patient and being able to accompany the patient to the visits Patients having received no vaccination with AFFITOPE AD02 History of questionable compliance to visit schedule, patients not expected to finish the clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Alzheimer</keyword>
	<keyword>Morbus Alzheimer</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Alzheimer Vaccine</keyword>
	<keyword>A-beta immunotherapy</keyword>
</DOC>